NVIDIA's (NVDA) overall Q2 performance is likely to have benefited from increasing investments in generative AI across the datacenter end market.
Vous n'êtes pas connecté
Expanding aging population and the increasing demand for affordable health products are likely to have boosted the performance of healthcare stocks in Q2. CI, UHS, HCA & THC are potential outperformers.
NVIDIA's (NVDA) overall Q2 performance is likely to have benefited from increasing investments in generative AI across the datacenter end market.
RBRK's fiscal second-quarter performance is likely to reflect benefits from its expanding clientele and increased demand for its data security...
PSTG's fiscal Q2 performance rides on robust demand for FlashBlade solutions, notably FlashArray//E and Flashblade //E offerings.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks....
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks....
Samsara's fiscal second-quarter performance benefits from expanding its customer base.
Samsara's fiscal second-quarter performance benefits from expanding its customer base.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks....
DSGX's Q2 fiscal 2025 performance is likely to have gained from robust demand for its differentiated offerings and buyout strategies.
HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt...